Retatrutide, from Soma Pharmaceuticals , is attracting increasing attention as a potential therapy for weight control . This dual-action compound integrates the activity of a GLP-1 receptor agonist and a GIP receptor agonist , designed to not only promote weight loss but also address underlying metabolic conditions . Early clinical data have shown